24 research outputs found
Kaplan–Meier curves for RFS in 883 ALN negative breast cancer patients by postoperative fever.
<p>Kaplan–Meier curves for RFS in 883 ALN negative breast cancer patients by postoperative fever.</p
Kaplan–Meier curves for RFS in 883 ALN negative breast cancer patients by HR/ERBB2(A) and tumor size (B).
<p>Kaplan–Meier curves for RFS in 883 ALN negative breast cancer patients by HR/ERBB2(A) and tumor size (B).</p
Annual relapse hazard rate for 883 ALN negative breast cancer patients by postoperative fever.
<p>Annual relapse hazard rate for 883 ALN negative breast cancer patients by postoperative fever.</p
Forest plot of meta-analysis on the disease-free survival in hormone receptor positive and negative patients for the addition of capecitabine to standard treatment.
<p>Forest plot of meta-analysis on the disease-free survival in hormone receptor positive and negative patients for the addition of capecitabine to standard treatment.</p
Forest plot of meta-analysis on the distant recurrence for the addition of capecitabine to standard treatment.
<p>Forest plot of meta-analysis on the distant recurrence for the addition of capecitabine to standard treatment.</p
Forest plot of meta-analysis on the disease-free survival in HER2 positive and negative patients for the addition of capecitabine to standard treatment.
<p>Forest plot of meta-analysis on the disease-free survival in HER2 positive and negative patients for the addition of capecitabine to standard treatment.</p
Forest plot of meta-analysis on the breast cancer specific survival for the addition of capecitabine to standard treatment.
<p>Forest plot of meta-analysis on the breast cancer specific survival for the addition of capecitabine to standard treatment.</p
Forest plot of meta-analysis on the disease-free survival for the addition of capecitabine to standard treatment.
<p>Forest plot of meta-analysis on the disease-free survival for the addition of capecitabine to standard treatment.</p
Forest plot of meta-analysis on the disease-free survival in triple negative patients for the addition of capecitabine to standard treatment.
<p>Forest plot of meta-analysis on the disease-free survival in triple negative patients for the addition of capecitabine to standard treatment.</p